Eli Lilly Stock Gets a Lift as New Lung Cancer Data Raises Hopes

What happened

Eli Lilly shares climbed nearly 1% in pre-market trading after clinical data showed its experimental drug olomorasib shrank tumors in 62% of patients when paired with immunotherapy and chemotherapy for an aggressive form of lung cancer.

Confirmed

Global impact / market context

If later randomized trials confirm these early results, olomorasib could become a new treatment option in a lung cancer type driven by the KRAS G12C mutation, which means a genetic change that fuels tumor growth, supporting future Lilly revenue.

Analyst inference

The data come from small single-group studies lacking randomized comparison groups, and the drug is unapproved. Investors appear to be pricing in hope ahead of the Phase 3 SUNRAY-01 trial, whose initial results are expected in the first half of 2027.

Analyst inference

What to watch

1. Phase 3 SUNRAY-01 trial results for olomorasib are expected in the first half of 2027, which will test whether the early tumor-shrinking results hold up in a larger randomized study. Confirmed
2. Watch whether Lilly files for regulatory approval of olomorasib, since the drug remains unapproved and any submission would mark a formal step toward reaching patients and generating sales. Proposed
3. Track how long tumor responses last in the Merck Keytruda combination study, because durable benefit without chemotherapy could widen the drug's use and strengthen Lilly's position versus rivals. Analyst inference

Evidence

• gurufocus.com